Aura Biosciences (NASDAQ:AURA) SVP Amy Elazzouzi Sells 8,549 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 8,549 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total value of $43,257.94. Following the transaction, the senior vice president owned 75,532 shares of the company’s stock, valued at $382,191.92. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 20th, Amy Elazzouzi sold 1,581 shares of Aura Biosciences stock. The stock was sold at an average price of $4.86, for a total value of $7,683.66.

Aura Biosciences Price Performance

Shares of AURA stock traded down $0.32 during trading hours on Tuesday, reaching $5.25. The company had a trading volume of 463,309 shares, compared to its average volume of 180,467. The company has a market cap of $333.38 million, a price-to-earnings ratio of -2.71 and a beta of 0.46. Aura Biosciences, Inc. has a 12 month low of $4.34 and a 12 month high of $8.03. The business has a fifty day simple moving average of $5.60 and a 200-day simple moving average of $5.97.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AURA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore assumed coverage on shares of Aura Biosciences in a research note on Tuesday, November 25th. They issued an “outperform” rating for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors have recently bought and sold shares of the company. Permanent Capital Management LP bought a new stake in shares of Aura Biosciences in the third quarter valued at $913,000. Levin Capital Strategies L.P. raised its stake in Aura Biosciences by 9.9% in the 2nd quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company’s stock valued at $9,362,000 after acquiring an additional 134,792 shares during the period. B Group Inc. lifted its holdings in Aura Biosciences by 21.2% during the second quarter. B Group Inc. now owns 572,576 shares of the company’s stock valued at $3,584,000 after purchasing an additional 100,000 shares during the last quarter. Franklin Resources Inc. boosted its position in Aura Biosciences by 5.9% during the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock worth $14,653,000 after purchasing an additional 130,221 shares during the period. Finally, Atria Investments Inc bought a new stake in shares of Aura Biosciences in the second quarter valued at approximately $190,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.